Valuation: Shield Therapeutics plc

Market Cap 5.94Cr 7.95Cr 7.09Cr 6.56Cr 11Cr 750.52Cr 11Cr 79Cr 31Cr 394.5Cr 30Cr 29Cr 1.26TCr P/E 2026 *
370x
P/E 2027 * 7.48x
Enterprise Value 7.78Cr 10Cr 9.29Cr 8.6Cr 15Cr 983.75Cr 15Cr 103.12Cr 40Cr 517.09Cr 39Cr 38Cr 1.65TCr EV / Sales 2026 *
1.46x
EV / Sales 2027 * 1.11x
Free-Float
38.49%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Shield Therapeutics plc

1 day+2.70%
1 week+8.57%
Current month-5.32%
1 month+21.28%
3 months-8.06%
6 months-39.36%
Current year-42.13%
1 week 5.05
Extreme 5.052
5.75
1 month 4.7
Extreme 4.7
6.1
Current year 3.7
Extreme 3.7
12.5
1 year 3.7
Extreme 3.7
12.5
3 years 1.06
Extreme 1.0625
12.5
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 24/07/2024
Director of Finance/CFO 50 01/09/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 01/02/2016
Chairman 70 18/06/2020
Director/Board Member 59 26/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/25 Free

Chief Executive Officer

15,47,262 0.1485%
13/02/25 Free

Chief Executive Officer

50,00,000 0.4800%
13/02/25 Buy

Chief Executive Officer

5,75,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
+2.70%+8.57%-25.49%-9.52% 7.94Cr
-1.01%+5.13%+58.93%+120.37% 1,14400Cr
-0.61%+1.52%+34.34%+70.28% 63TCr
-1.48%+0.47%+23.08%+96.78% 51TCr
+0.54%+8.95%+39.45%+64.02% 38TCr
+1.07%+1.70%+71.06%+45.02% 37TCr
+0.30%+6.35%+21.84%+49.62% 29TCr
-0.03%+6.04%+0.40%+20.94% 26TCr
-0.14%+2.87%+45.56%+60.53% 24TCr
-1.88%+0.02%+23.77%+98.00% 19TCr
Average +0.00%+6.25%+29.29%+61.60% 40.08TCr
Weighted average by Cap. -0.42%+6.91%+40.78%+81.10%

Financials

2026 *2027 *
Net sales 5.35Cr 7.16Cr 6.38Cr 5.91Cr 10Cr 675.99Cr 10Cr 71Cr 28Cr 355.32Cr 27Cr 26Cr 1.13TCr 6.99Cr 9.36Cr 8.34Cr 7.73Cr 13Cr 883.71Cr 13Cr 93Cr 36Cr 464.51Cr 35Cr 34Cr 1.48TCr
Net income 3L 3L 3L 3L 5L 3.26Cr 5L 34.18L 13.41L 1.71Cr 12.96L 12.69L 5.46Cr 77.44L 1.04Cr 92.42L 85.57L 1.46Cr 98Cr 1.48Cr 10Cr 4.03Cr 51Cr 3.89Cr 3.81Cr 163.93Cr
Net Debt 1.85Cr 2.47Cr 2.2Cr 2.04Cr 3.48Cr 233.23Cr 3.52Cr 24Cr 9.59Cr 122.59Cr 9.27Cr 9.08Cr 390.65Cr 1.8Cr 2.41Cr 2.15Cr 1.99Cr 3.39Cr 227.48Cr 3.43Cr 24Cr 9.36Cr 119.57Cr 9.04Cr 8.85Cr 381.02Cr
Projected Income Statement - Annual - Shield Therapeutics plc
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
21/26/21 GBX 5.700 +2.70% 8,21,989
20/26/20 GBX 5.550 +3.74% 29,93,757
19/26/19 GBX 5.350 +2.88% 15,85,170
16/26/16 GBX 5.200 0.00% 5,90,860
15/26/15 GBX 5.200 -0.95% 7,10,556
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Shield Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0555GBP
Average target price
0.1667GBP
Spread / Average Target
+200.31%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shield Therapeutics plc